• Laura Distelmaier, Sabine Ehrlich, Claudia Wallrauch, Michael von Bergwelt-Baildon, and Camilla Rothe.
• Hämatologie und Onkologie, Medizinische Klinik und Poliklinik 3, Ludwig-Maximilians-Universität München, München, Deutschland.
• Dtsch. Med. Wochenschr. 2024 Nov 1; 149 (22): 133513401335-1340.

AbstractApproximately one third of the German population has a migration background.According to the federal office for migration, in 2022 around 2,7 million people have taken refuge or have immigrated to Germany, causing major challenges for our health system. In this article, important infectious diseases, and non-infectious conditions like hemoglobinopathies are presented. To date, especially the latter are not common in Germany and must therefore move more into focus when taking care of migrants. Furthermore, new treatment options for hemoglobinopathies have been approved in the last couple of years, starting with the introduction of Luspatercept a few years ago for Beta-Thalassemias and in 2023 the introduction of Voxelotor for sickle cell disease. In 2024 the gene therapy with Exagamglogen-Autotemcel using the CRISPR/Cas molecular scissor was authorized as a new promising treatment for both conditions.Thieme. All rights reserved.

6 keywords...

hide…